35.75 0.15 (0.42%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 43.35 | 1-year : | 45.31 |
Resists | First : | 37.11 | Second : | 38.79 |
Pivot price | 35.35 | |||
Supports | First : | 34.39 | Second : | 28.61 |
MAs | MA(5) : | 35.08 | MA(20) : | 35.88 |
MA(100) : | 31.98 | MA(250) : | 30.61 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 30.9 | D(3) : | 18 |
RSI | RSI(14): 52 | |||
52-week | High : | 38.79 | Low : | 23.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SBIO ] has closed below upper band by 33.4%. Bollinger Bands are 38.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 35.94 - 36.09 | 36.09 - 36.24 |
Low: | 34.96 - 35.12 | 35.12 - 35.27 |
Close: | 35.5 - 35.76 | 35.76 - 36.03 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Thu, 29 Feb 2024
2024-02-29 | ARCA:SBIO | Press Release | ALPS Medical Breakthroughs ETF - Stockhouse Publishing
Tue, 06 Feb 2024
There Could Be Signs of Life for Biotech ETFs - ETF Trends
Mon, 08 Jan 2024
3 Biotech ETFs to Bet on Now - Nasdaq
Fri, 29 Dec 2023
5 Market-Beating Sector ETFs of December - Yahoo Finance
Thu, 28 Dec 2023
Biotech ETF SBIO's Momentum Strong to End 2023 - ETF Trends
Thu, 14 Dec 2023
Biotech ETF SBIO Sees Buy Signal Amid Hot Returns - ETF Trends
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
AMEX
|
|
Sector:
Real Estate
|
|
Industry:
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |